Financing channel feed

Short­ly af­ter its lat­est mega-round, Sir­naomics CEO Patrick Lu says it's time to go pub­lic

4 years ago

Nas­daq rings in Jonathan Lim's next can­cer play, Pfiz­er-backed start­up and Har­vard spin­out with col­lec­tive $534M raise un­der their belts

4 years ago

Mak­ing a name for it­self in Covid-19 test­ing, Hong Kong's Pre­net­ics is the lat­est biotech SPAC merg­er — re­port

4 years ago

EX­CLU­SIVE: Shape Ther­a­peu­tics rais­es $112M in bid to make RNA edit­ing — and a whole lot else — a re­al­i­ty

4 years ago
Cell/Gene Tx

A Chi­nese I/O biotech look­ing to turn around an old No­var­tis pro­gram gets a new fundraise af­ter launch­ing PhI­II study

4 years ago

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and be­yond

4 years ago
Cell/Gene Tx

Dis­cov­ery by Shang­hai sci­en­tists in­spires new plan of AT­TEC for pro­tein degra­da­tion

4 years ago
Startups
China

Ri­bon Ther­a­peu­tics is look­ing to break the mold for PARP in­hibitors and has a slate of Big Phar­ma back­ers on board

4 years ago

AI start­up En­tos looks to one-up the rest of the field by fold­ing quan­tum me­chan­ics in­to its dis­cov­ery plat­form

4 years ago
Startups

Flush with cash, com­pu­ta­tion­al chem­istry pi­o­neer Nim­bus con­sid­ers next steps. Is an IPO in the fu­ture?

4 years ago

Bap­tized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to car­ry on with pipeline for in­fec­tious dis­eases and be­yond

4 years ago
China

Per­cep­tive hits the pric­ing sweet spot on its lat­est SPAC, kick­start­ing the search for next for­ev­er part­ner

4 years ago

With Eli Lil­ly's back­ing, a team of Seagen vet­er­ans with ADC chops is look­ing to crash the Chi­nese on­col­o­gy par­ty

4 years ago
China

David Liu takes the wraps off $315M launch round for Prime Med­i­cine and new CRISPR tech that gave Bob Nelsen a 'holy crap' mo­ment

4 years ago
Startups
Cell/Gene Tx

As 5 more biotechs file their IPOs, one Nas­daq of­fi­cial does­n't see mo­men­tum slow­ing down any­time soon

4 years ago

No­vo Seeds launch­es a new neu­ro biotech as Alzheimer's R&D booms

4 years ago

A Mubadala-backed biotech is us­ing pa­tient tu­mor tis­sue grown in a petri dish to change pre­ci­sion on­col­o­gy

4 years ago
AI

Spurring a biotech craze of its own, the UK plots out pub­lic-pri­vate in­vest­ment plan as part of $1B+ in­dus­try in­fu­sion

4 years ago

Nu­va­lent joins the IPO par­ty less than 6 months af­ter launch, while Icosavax kicks its 'soc­cer bal­l' VLPs to Nas­daq

4 years ago

Af­ter sell­ing its spin­out to Bay­er in a $875M-plus deal, NeRRe Ther­a­peu­tics grabs $28M for some 'un­fin­ished busi­ness'

4 years ago

Start­up boast­ing 'gob­stop­per-style' vac­cine de­liv­ery draws big part­ner­ships — and back­ing from Ad­ju­vant Cap­i­tal

4 years ago
Startups

Eli Lil­ly adds a $15M eq­ui­ty sweet­en­er for its plat­form part­ner in saR­NA

4 years ago

No hol­i­day for biotech IPOs as Rally­bio and Sophia Ge­net­ics sub­mit their Nas­daq pitch­es

4 years ago

Busy IPO week winds down as two more biotechs — and one look­ing to im­prove clin­i­cal tri­als — file for pub­lic de­buts

4 years ago
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times